









































Nonetheless,	 the	 topic	of	 treatment	 interruption	 is	 still	actively	under	discussion	since	causes	 for	 treatment	 failure,	 following	 interruption,	 remain	poorly	understood,	although	missed	drug	doses	 result	 in	decreased	drug
concentration	and	consequent	effectiveness.	 In	addition,	 loss	of	viral	control	and/or	 increase	 in	drug	resistant	mutations	may	contribute		[17].	Given	that	a	clinical	predictor	 for	 treatment	 failure	has	not	been	 found,	mathematical
modelling	has	a	role	in	using	and	augmenting	existing	clinical	data	to	explore	alternative	solutions.
1.2	Modelling	HIV:	differential	equations	(top-down)




The	 system	 consists	 of	 three	 separate	 ‘units’	 or	 entities,	 (often	 designated	 in	 epidemiological	 studies	 as	 a	 ‘compartmental	 model’),	 while	 in	 our	 example,	 the	 ‘units’	 are	 the	 three	 cell	 types,	 where	 variable	 denotes




















where,	 in	 addition	 to	 the	 system	 in	 (1),	 Eqs.	 (2)	 include	 latently-infected	 cells	 and	 immune	 response	 captured	 by	 the	 ‘effector	 cells’3	 compartment	 .	 Additional	 parameters	 include	 the	 fraction	 of	 cells	 entering	 the
reservoir	upon	infection,	and	those	exiting	the	reservoir	and	becoming	actively	infectious,	with	rate	 .	Inside	the	reservoir,	cells	proliferate	and	die	according	to	rates	( ).	Effector	cells	reduce	the	amount	of	infected	cells	through
the	first-order	relation	and	rate	 .	Size	of	the	effector	cell	compartment	depends	on	a	constant	formation	rate	term	 and	first-order	death	rate	 similar	to	the	susceptible	cell	compartment.	Moreover,	effector	cells	are	assumed	to
proliferate	and	die	following	Michaelis–Menten	kinetics		[23],	where	infected	cells	serve	as	‘substrate’,	with	maximum	rates	of	 and	 and	Michaelis–Menten	constants	of	 and	 respectively.
The	ODE-approach	assumes	all	model	properties	to	be	continuous	variables.	Thus,	the	system	observed	is	envisaged	as	a	‘well-mixed	container’,	although	this	applies	loosely	at	best	for	the	human	organism,	which	naturally
consists	of	sections	of	different	tissues	and	cavities,	which	are	separated	anatomically	but	connected	through	transport	mechanisms,	such	as	the	blood	and	lymph	stream	and	which	are	populated	by	discrete,	cellular	entities.	In	the
case	 of	HIV,	 infections	 occur	 predominantly	 in	 lymphatic	 tissues	where	 the	 greatest	 proportion	 of	 susceptible	 lymphocytes	 resides.	 Intuitively,	 one	would	 assume	 that	 the	 neighbourhood	 of	 virus-shedding	 infected	 cells	 is	more
susceptible	to	infection	than	that	of	remote	cells.	There	is	also	evidence	that	HIV	infection	is	more	likely	to	occur	through	cell-to-cell	contacts	than	uptake	of	free	viral	particles		[24],	which	appears	to	support	this	view.
To	analyse	this	spatial	heterogeneity	associated	with	HIV	infections,	additional	dimensions	may	be	introduced	in	models	of	Differential	Equation	type	(by	means	of	partial	differentiation	terms).	The	resulting	systems	of	Partial
Differential	Equations	 (PDEs)	are	widely	used	 to	mathematically	model	biological	 tissues	 in	oncology	and	 for	 liver	conditions,	 such	as	hepatitis		[25].	For	HIV,	a	 system	of	coupled	PDEs	on	a	 regular	grid	has	been	analysed	 	 [26],
assuming	viral	diffusion	and	spatial	dependence	of	healthy	cell	production	given	by

















The	top-down	approach	described	above	derives	fundamental	relations	for	a	specific	system,	 including	further	detail	as	more	biological	knowledge	 is	 incorporated.	However,	biological	organisms	consist	of	distinct	entities
operating	over	multiple	scales,	from	genes	and	individual	cells	to	organs,	with	emergent	behaviour	at	fundamental	levels	contributing	to	that	of	the	overall	system.	A	bottom-up	modelling	approach	takes	account	of	changes	to	these
separate	entities	to	infer	outcomes	overall.	Therefore	bottom-up	approaches	appear	to	be	well-suited	to	model	biological	systems	on	the	premise	that	the	underlying	mechanisms	are	known	in	sufficient	detail.	These	concepts,	however,
	 	 		 	 		 	
		 	 		 	
		 	 		 	 		 	







































Immune	response Resistance Pharmacology Latent	reservoir Spatial	aspects
ODE 35 14 20 12 13 0
ABM 5 5 0 0 5 5
Exponential 1 0 0 0 0 0
SDE 1 0 1 0 0 0
Stoch.	Sim. 2 0 2 1 2 0
In	total,	44	separate	modelling	studies	were	identified,	(see	Table	1).	The	degree	of	biological	realism	varied	greatly	across	models	examined.	Earlier	studies	of	treatment	interruptions	were	published	over	the	time	period	from






of	 infected	or	healthy	cells.	Treatment	acts	as	an	external	 input.	Various	designs	have	been	proposed,	 from	that	of	continuous	dosage		[47],	 to	discrete	drug	administration		[48].	Once	again,	model	parameters	were	based	on	 the
literature.
A	novel	 optimal	 control	 approach,	 for	 observation	of	 treatment	 interruptions,	has	been	 reported	also	by		[49].	The	Castiglione	et	al.	 C-IMMSIMM	model	 is	 agent-based	 and	 includes	 a	 very	 detailed	 reproduction	 of	major







A	small	sub-	group	sub-group	(nine),	 of	 the	modelling	 studies	 identified,	 used	 clinical	 data	 to	 estimate	parameters	 of	ODE	models.	We	 found	 that	 clinical	 datasets	were	 sourced	 from	 studies,	 conducted	over	 the	 timespan,
























































Considering	 the	 impact	 of	 treatment	 interruption	 in	 the	Gonzalez	 et	al.	model		[39],	 lattice	 structure	 appears	 to	 preserve	 infected	 cell	 configurations	 prior	 to	 treatment	 initiation.	 Clusters	 of	 infected	 cells	 can	 continue	 to	 propagate	 during
treatment.	In	consequence,	control	of	further	spread	through	protected	cell	states	is	lost	upon	treatment	interruption	and	infected	cells	re-occupy	this	space,	with	rapid	rebound	of	infected	cell	numbers.	Fig.	3	shows	different	baseline	levels	of	infected-cell
concentrations	due	to	different	 treatment	 initiation	 times.	After	simulated	 treatment	 initiation,	viral	 levels	stabilise	at	a	certain	 level,	which	appears	 to	depend	on	baseline	viral	 levels.	After	simulated	 treatment	 interruption	 (causing	an	effect	of	viral
rebound	as	shown	in	Fig.	1),	and	subsequent	re-initiation	with	the	same	effectiveness	as	that	in	pre-interruption,	viral	levels	stabilise	again.	Interestingly,	these	levels	appear	to	be	raised	permanently	due	to	the	interruption.
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Footnotes
1CD4+		T-Lymphocytes	act	as	indicators	to	impairment	of	the	immune	system	due	to	HIV	infection.	Low	levels	of	these	in	blood	are	associated	with	opportunistic	disease	and	onset	of	AIDS.
2CD4+-guided	STI	schedules	for	treatment	interruption	and	re-initiation,	base	decisions	on	the	violation	of	predefined	limits	of	patient	CD4+		count	in	blood.
3‘Effector	cells’	in	the	cellular	immune	system,	after	activation	from	a	naïve	state,	cause	a	cytotoxic	response	to	pathogen.	CD8+		T-cells	is	the	effector	cell	type,	found	to	be	most	effective	in	the	HIV	context.
Highlights
• Treatment	Interruption	models	almost	entirely	Differential	Equation-based	to	date.
• Model	calibration	reliant	on	a	small	number	of	datasets,	more	than	a	decade	old.
• Bottom-up	methods	can	help	enhance	aspects	of	the	problem.
• Cellular	Automata	models	may	give	insights	into	e.g.	latent	reservoir	persistence.
• Treatment	interruptions	though	pose	challenges	to	existing	models	of	either	type.
